ClinicalTrials.Veeva

Menu

A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices

Lilly logo

Lilly

Status and phase

Completed
Phase 1

Conditions

Healthy

Treatments

Device: Test
Device: Reference
Drug: LY3437943

Study type

Interventional

Funder types

Industry

Identifiers

NCT06003465
18530
J1I-MC-GZBX (Other Identifier)

Details and patient eligibility

About

The main purpose of this study is to look at the amount of the study drug, LY3437943, that gets into the blood stream and how long it takes the body to get rid of it when given using two different devices. The study will also evaluate the safety and tolerability of LY3437943 and information about any side effects experienced will be collected. For each participant, the total duration of the study will be approximately 16 weeks, including screening.

Enrollment

57 patients

Sex

All

Ages

18 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Healthy males or non-pregnant females as determined by medical history, physical examination, and other screening procedures
  • Body mass index (BMI) between 18.5 and 32.0 kilograms per meter squared (kg/m²), inclusive
  • Have clinical laboratory test results, blood pressure and pulse rate that are acceptable for the study
  • Are agreeable to receiving study treatment by injections under the skin
  • Males who agree to use highly effective/effective methods of contraception and women not of childbearing potential (postmenopausal or oophorectomized)

Exclusion criteria

  • Have or used to have health problems that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study
  • Smoke more than the equivalent of 10 cigarettes per day
  • Is a known user of drugs of abuse
  • Have known allergies to LY3437943 or related compounds

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

57 participants in 2 patient groups

LY3437943 - Test
Experimental group
Description:
A single dose of LY3437943 administered by subcutaneous (SC) injection via a test device (test formulation)
Treatment:
Drug: LY3437943
Device: Test
LY3437943 - Reference
Active Comparator group
Description:
A single dose of LY3437943 administered by SC injection via a reference device (reference formulation)
Treatment:
Drug: LY3437943
Device: Reference

Trial contacts and locations

4

Loading...

Central trial contact

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems